Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

Detalles Bibliográficos
Autores principales: Bozorgmehr, Farastuk, Chung, Inn, Christopoulos, Petros, Krisam, Johannes, Schneider, Marc A., Brückner, Lena, Mueller, Daniel Wilhelm, Thomas, Michael, Rieken, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416363/
https://www.ncbi.nlm.nih.gov/pubmed/37563548
http://dx.doi.org/10.1186/s12885-023-11270-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416363/
https://www.ncbi.nlm.nih.gov/pubmed/37563548
http://dx.doi.org/10.1186/s12885-023-11270-x

Ejemplares similares